Literature DB >> 1848818

Expression of three human beta-adrenergic-receptor subtypes in transfected Chinese hamster ovary cells.

K M Tate1, M M Briend-Sutren, L J Emorine, C Delavier-Klutchko, S Marullo, A D Strosberg.   

Abstract

The genes coding for three pharmacologically distinct subtypes of human beta-adrenergic receptors (beta 1 AR, beta 2 AR and beta 3 AR) were transfected for expression in Chinese hamster ovary (CHO) cells. Stable cell lines expressing each receptor were analyzed by ligand binding, adenylate cyclase activation and photoaffinity labeling, and compared to beta AR subtypes observed in previously described tissues, primary cultures and transfected cell lines. Each of the three receptor subtypes displayed saturable [125I]iodocyanopindolol-binding activity. They showed the characteristic rank order of potencies for five agonists, determined by measuring the accumulation of intracellular cAMP. These recombinant cell lines express a homogeneous population of receptors and display the known pharmacological properties of beta 1 AR and beta 2 AR, in human tissues. It is therefore likely that the pattern of ligand binding and adenylate cyclase activation, mediated by the new beta 3 AR in CHO cells, also reflects the yet-undetermined pharmacological profile in humans.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1848818     DOI: 10.1111/j.1432-1033.1991.tb15824.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  18 in total

1.  Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.

Authors:  C Hoffmann; M R Leitz; S Oberdorf-Maass; M J Lohse; K-N Klotz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-01-17       Impact factor: 3.000

2.  Induction of a pharmacologically active clonotypic B cell response directed to an immunogenic region of the human beta 2-adrenergic receptor.

Authors:  J G Guillet; R Lengagne; Y Magnusson; K Tate; A D Strosberg; J Hoebeke
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

3.  β(3) Receptors: Role in Cardiometabolic Disorders.

Authors:  Shraddha V Bhadada; Bhoomika M Patel; Anita A Mehta; Ramesh K Goyal
Journal:  Ther Adv Endocrinol Metab       Date:  2011-04       Impact factor: 3.565

Review 4.  Tools to study beta3-adrenoceptors.

Authors:  Wim Vrydag; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-09       Impact factor: 3.000

5.  Comparison of three radioligands for the labelling of human beta-adrenoceptor subtypes.

Authors:  Nadja Niclauss; Martina B Michel-Reher; Astrid E Alewijnse; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-10-07       Impact factor: 3.000

Review 6.  Modification of beta-adrenoceptor signal transduction pathway by genetic manipulation and heart failure.

Authors:  X Wang; N S Dhalla
Journal:  Mol Cell Biochem       Date:  2000-11       Impact factor: 3.396

7.  Down-regulation of beta3-adrenergic receptor expression in rat adipose tissue during the fasted/fed transition: evidence for a role of insulin.

Authors:  K E Hadri; C Charon; J Pairault; S Hauguel-De Mouzon; A Quignard-Boulangé; B Fève
Journal:  Biochem J       Date:  1997-04-15       Impact factor: 3.857

8.  Characterization of propranolol-resistant (-)-[125I]-cyanopindolol binding sites in rat soleus muscle.

Authors:  S J Roberts; P Molenaar; R J Summers
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

9.  Multiple lipolysis defects in the insulin resistance (metabolic) syndrome.

Authors:  S Reynisdottir; K Ellerfeldt; H Wahrenberg; H Lithell; P Arner
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

10.  Expression of two human beta-adrenergic receptors in Escherichia coli: functional interaction with two forms of the stimulatory G protein.

Authors:  M Freissmuth; E Selzer; S Marullo; W Schütz; A D Strosberg
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.